Mergers & Acquisitions ·
GSK plc has entered an agreement to acquire Nuvalent, Inc. for an estimated aggregate equity value of $10.6 billion…
GSKGSK plc
GSK plc has entered an agreement to acquire Nuvalent, Inc. for an estimated aggregate equity value of $10.6 billion (£8.0 billion). The acquisition includes oncology assets such as zidesamtinib (NVL-520) and neladalkib (NVL-655) for non-small cell lung cancer, which are currently under FDA review with target decision dates in late 2026. GSK will commence a tender offer at $124 per share in cash, representing a 40% premium to the last closing price. GSK is a global biopharma company focused on disease prevention and treatment.